Drug Profile
Ecteinascidin 722
Alternative Names: ET 722Latest Information Update: 21 Jul 2009
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Developer PharmaMar
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 Jul 2009 Discontinued - Preclinical for Cancer in Spain (Parenteral)
- 08 Oct 1999 ET 722 is now called ecteinascidin 722
- 08 Oct 1999 Suspended-Preclinical for Cancer in Spain (Parenteral)